论文部分内容阅读
目的探讨促红细胞生成素(erythropoitin,EPO)治疗早产儿贫血的临床效果。方法将84例早产儿(胎龄30-35周)按入院顺序随机分为对照组与观察组各42例,对照组采用常规治疗(每天口服铁剂5mg/kg,维生素C 25mg,维生素E 25mg),观察组在常规治疗的基础上,自出生第7d给予促红细胞生成素(erythropoitin,EPO),每次250IU/kg,皮下注射,隔日1次,每周3次,持续用药4周。治疗期间避免诊断性抽血或输血,所有新生儿均观察至出生第7周,检测并分析治疗前后血常规红细胞(RBC)、红细胞压积(HCT)及血红蛋白(Hb)等指标的变化。结果两组患儿治疗前、后RBC、HCT及Hb等指标均有不同程度的上升,其中对照组上升不明显,与治疗前相比无统计学意义(P>0.05);治疗组4周治疗后RBC、HCT、Hb指标较治疗前明显上升,治疗前、后相比较有显著性差异(P<0.05),且观察组治疗后各项指标检测结果与对照组相比较,具有显著性差异(P<0.05)。结论 EPO治疗早产儿贫血效果显著,安全性较好,值得临床推广。
Objective To investigate the clinical effect of erythropoitin (EPO) on anemia in premature infants. Methods 84 cases of preterm infants (gestational age 30-35 weeks) were randomly divided into control group and observation group according to the sequence of admission. The control group received routine treatment (5 mg / kg oral iron daily, 25 mg vitamin C, 25 mg vitamin E ). On the basis of routine treatment, the observation group received erythropoitin (EPO) on the 7th day after birth for 250IU / kg, subcutaneously, once every other day, three times a week for 4 weeks. During the treatment to avoid diagnostic blood or blood transfusion, all newborns were observed until the first 7 weeks of life, before and after treatment to detect and analyze the changes of blood RBC, hematocrit (HCT) and hemoglobin (Hb) and other indicators. Results Before and after treatment, the indexes of RBC, HCT and Hb in both groups increased to some extent, but the increase in the control group was not obvious, which was not statistically significant compared with that before treatment (P> 0.05) The indexes of RBC, HCT and Hb were significantly increased compared with that before treatment, before and after treatment (P <0.05), and there was significant difference between the observation group and control group P <0.05). Conclusion EPO treatment of anemia in preterm children with significant effect, safety is good, worthy of clinical promotion.